Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.35 |
| ▸ | CNR2 | P34972 | 2/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.33 |
| ▸ | SLC2A1 | P11166 | 6/20 | 0.33 |
| ▸ | SLC2A3 | P11169 | 6/20 | 0.33 |
| ▸ | SLC2A4 | P14672 | 6/20 | 0.33 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
| ▸ | PPARG | P37231 | 2/20 | 0.32 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10076313 | 0.94 | SLC2A1 (0.34) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL11928445 | 0.92 | SLC2A1 (0.35) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL10083881 | 0.90 | SLC2A1 (0.35) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL13085420 | 0.90 | SLC2A1 (0.34) | CNR1CNR2SLC2A1SLC2A3SLC2A4 | |
| SCHEMBL10076311 | 0.89 | SLC2A1 (0.35) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL13085547 | 0.89 | SLC2A1 (0.35) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL13085283 | 0.89 | SLC2A1 (0.35) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL13085372 | 0.89 | SLC2A1 (0.39) | SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL10076309 | 0.88 | SLC2A1 (0.32) | CNR1SLC2A1SLC2A3SLC2A4SLC2A2 | |
| SCHEMBL10089878 | 0.88 | IDH1 (0.39) | CNR1CNR2SLC2A1SLC2A3SLC2A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791143-B2 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2014-07-29 | — | — | US | disclosed |
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | BAYER CROPSCIENCE AG (DE) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010249-A1 | Anthranilic diamide derivatives having cyclic side-chains | DDT, ADCY1, ANTXR2 | CNR1 984/4885CNR2 1011/4885PHGDH 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.